Context-specific synthetic T cell promoters from assembled transcriptional elements
Overview
The study creates synthetic promoters for CAR-T cells. T cells nucleofected with piggyBac transposase were transferred to G-Rex® culture vessels for 21 days of expansion.
What this paper found
Randomly ligating eleven transcription response elements upstream of an IL-2 minimal promoter produced a lentiviral library from which CD19CAR-directed screening in human CD8+ T cells isolated inducible synthetic promoters (iSynPros) that switch on only with antigen. Eight of eight candidates induced GFP at every recurrent CD19+ LCL exposure and returned to baseline, and iSynPro1 combined the tightest OFF state with the strongest induction. Induction required CD3 zeta signal 1, was abrogated by dasatinib, and did not follow costimulation alone. In mice, iSynPro1 activity stayed confined to antigen-bearing tumors. iSynPro1-driven LASI-7/21 cleared Nalm-6 in four of five mice with no deaths after clearance, whereas constitutive LASI-7/21 left 60% of mice moribund.
Note: Preclinical work in cell culture and mouse xenograft models. The authors note that the library was built from eleven T cell activation-specific response elements ligated as contiguous blocks, and that greater library complexity, such as variable spacing between elements or a wider element set, could better mirror naturally occurring promoters.
Taken together, we conclude that iSynPro1 regulation enables simultaneous CAR T cell functional enhancements by a mitogenic transgene while preventing toxicity due to unrestricted T cell growth. — Jacob Appelbaum, Jia Wei, Rithun Mukherjee, Taylor Ishida, James Rosser, Chris Saxby, John Chase, Marc Carlson, Cassie Sather, Wolfgang Rahfeldt, Michael Meechan, Michael Baldwin, Lindsay Flint, Cailyn Spurrell, Joshua Gustafson, Adam Johnson, Michael Jensen, Research Square (preprint)
Study details
- Authors
- Jacob Appelbaum, Jia Wei, Rithun Mukherjee, Taylor Ishida, James Rosser, Chris Saxby, John Chase, Marc Carlson, Cassie Sather, Wolfgang Rahfeldt, Michael Meechan, Michael Baldwin, Lindsay Flint, Cailyn Spurrell, Joshua Gustafson, Adam Johnson, Michael Jensen
- Institution
- Fred Hutch Cancer Center · Seattle Children's Research Institute · Fred Hutchinson Cancer Research Center
- Journal
- Research Square (preprint)
- Year
- 2023
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy · Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
Primary human CD4+ or CD8+ T cells were nucleofected with a piggyBac donor plasmid and transposase RNA on the Lonza 4D system, then transferred into a G-Rex® culture vessel pre-seeded with the CD4-/CD8- PBMC fraction. Expansion ran in X-Vivo 15 with 2% KnockOut serum replacement, 80 U/mL IL-2, 20 ng/mL IL-4, 10 ng/mL IL-7 and 20 ng/mL IL-21. Medium was replaced twice weekly and the cells were expanded for 21 days before use in the in vitro and in vivo assays.
Note: The CD4-/CD8- PBMC fraction seeded into the vessel ahead of the nucleofected T cells is the fraction set aside when CD4+ and CD8+ cells were purified from healthy-donor PBMCs with RoboSep.
Explore related
Full citation
Appelbaum J, Wei J, Mukherjee R, et al. Context-specific synthetic T cell promoters from assembled transcriptional elements. Research Square. 2023. Preprint.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.